Drug Trial Radar · NCT00309244
Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up
Last checked: Nov 20, 2026Latest source record: Oct 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
677
Actual
Start
Feb 2006
Primary completion
Aug 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Mannkind CorporationIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this 13 month study (12 month treatment period and 1 month follow-up period) is to determine whether inhaled insulin is safe and effective in the treatment of type 2 diabetes.
Conditions
- Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation PowderDrug
Inhalation, 15U/30U
70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)Drug
BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c to Week 52Time frame: Baseline to Week 52
Locations
151 sites in 10 countries. Site status is shown where the registry gives one.
Coastal Clinical Research Inc
Mobile, Alabama
Quality of Life Medical & Research Center
Tucson, Arizona
Southern Arizona VA Healthcare System
Tucson, Arizona
Tucson Clinical Research
Tucson, Arizona
International Clinical Research Network
Chula Vista, California
Saad Hijazi MD Inc
Fresno, California
Valley Research
Fresno, California
Diabetes/Lipid Management and Research Center
Huntington Beach, California
South Bay Clinical Research
Inglewood, California
Southern California Endocrine Center
Pasadena, California
Coastal Biomedical Research Inc
Santa Monica, California
Diabetes Research Center
Tustin, California
University of Miami Diabetes Research Institute
Miami, Florida
International Research Associates LLC
Miami, Florida
Laureate Clinical Research Group
Atlanta, Georgia
Atlanta Pharmaceutical Research Center
Dunwoody, Georgia
North Atlanta Endocrinology & Diabetes PC
Lawrenceville, Georgia
Atlanta Center for Clinical Research
Roswell, Georgia
John H Stoger Jr Hospital of Cook County
Chicago, Illinois
Clintell Inc
Skokie, Illinois
Clintell Inc (Ellyin)
Skokie, Illinois
Medical Research of Louisiana
Metairie, Louisiana
Joslin Diabetes Center University of Maryland Medicine
Baltimore, Maryland
James A Dicke MDPA
Towson, Maryland
Wayne State University
Detroit, Michigan
Michigan Institute of Medicine
Livonia, Michigan
KMED Research
Saint Clair Shores, Michigan
Radiant Research Inc (Minneapolis)
Edina, Minnesota
International Diabetes Center
Minneapolis, Minnesota
Center for Urologic Clinical Trials University of Minnesota
Minneapolis, Minnesota
Amin Radparvar's Private Practice
City of Saint Peters, Missouri
MedEx Healthcare Research Inc
St Louis, Missouri
Billings Clinic Research Division
Billings, Montana
Montana Health Research Institute
Billings, Montana
Creighton Diabetes Center
Omaha, Nebraska
New Mexico Clinical Research & Osteoporosis Center
Albuquerque, New Mexico
University of New Mexico HCS
Albuquerque, New Mexico
Winthrop University Hospital
Mineola, New York
North Shore Diabetes and Endocrine Associates
New Hyde Park, New York
Univeristy of Physicians Group Endocrine Division
Staten Island, New York
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.